The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.
Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.
The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.
Recent Videos
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Oncotype DX Used for Patients With Breast Cancer to Guide Therapy
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer
Mitigating Toxicities With Oral SERDs and Other Breast Cancer Therapies
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
Breast Cancer Study Shows Minimal Score Variation After Radiation Boost
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
Shortened Radiation Trial Advances Breast Cancer Treatment
Understanding the Significance of ESR1 Mutations in Breast Cancer
Related Content
